Published in Ann Pharmacother on April 26, 2005
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Evaluation of a required senior research project in a doctor of pharmacy curriculum. Am J Pharm Educ (2011) 1.96
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation (2008) 1.44
The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol (2006) 1.27
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost (2010) 0.96
Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review. Iran J Pharm Res (2016) 0.95
Effect of patient-specific factors on weekly warfarin dose. Ther Clin Risk Manag (2007) 0.91
Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion? PLoS Med (2005) 0.82
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81
Atrial Fibrillation and Race - A Contemporary Review. Curr Cardiovasc Risk Rep (2013) 0.80
An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. Eur J Clin Pharmacol (2014) 0.78
Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? Can J Cardiol (2012) 0.77
Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity? J Multidiscip Healthc (2015) 0.77
Relationship between the Occurrence of Thromboembolism and INR Measurement Interval in Low Intensity Anticoagulation after Aortic Mechanical Valve Replacement. Korean J Thorac Cardiovasc Surg (2011) 0.77
Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics. BMC Genet (2014) 0.77
The need for multicentre cardiovascular clinical trials in Asia. Nat Rev Cardiol (2013) 0.75
Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population. Med Sci Monit (2015) 0.75
Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Front Pharmacol (2017) 0.75
Prediction of biogeographical ancestry from genotype: a comparison of classifiers. Int J Legal Med (2016) 0.75
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
Total knee arthroplasty in hemophilic arthropathy. J Bone Joint Surg Am (2002) 2.21
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol (2010) 2.16
Bending the curve toward increased use of generic drugs. JAMA Intern Med (2013) 2.00
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood (2003) 1.60
Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med (2004) 1.44
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood (2008) 1.03
Famotidine and long QT syndrome. Am J Cardiol (2004) 0.94
Pharmacogenetics: from discovery to patient care. Am J Health Syst Pharm (2009) 0.93
Survey on warfarin pharmacogenetic testing among anticoagulation providers. Pharmacogenomics (2009) 0.93
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.93
A review of three stand-alone topical thrombins for surgical hemostasis. Clin Ther (2009) 0.92
Pros and cons of dabigatran. Am J Health Syst Pharm (2011) 0.89
Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother (2002) 0.87
Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg (2004) 0.84
Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Pharmacotherapy (2011) 0.82
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion (2005) 0.80
Impact of pharmacists' interventions on the pediatric discharge medication process. Ann Pharmacother (2004) 0.79
Emergency department management of patients on warfarin therapy. Ann Emerg Med (2011) 0.76
In reply. JAMA Intern Med (2013) 0.75
Coagulopathy, marantic endocarditis, and cerebrovascular accidents as paraneoplastic features in medullary thyroid cancer--case report and review of the literature. Thyroid (2003) 0.75
Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion (2006) 0.75
Heart transplantation and altered drug response, Part II: pharmacologic management of post-transplantation complications. Prog Cardiovasc Nurs (2006) 0.75
Thrombocytopenia associated with antithrombotic therapy in acute coronary syndrome. Prog Cardiovasc Nurs (2003) 0.75
Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update. Pharmacotherapy (2012) 0.75